Last 7 days
-0.9%
Last 30 days
98.9%
Last 90 days
161.1%
Trailing 12 Months
143.7%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 402.9B | 94.9B | -1.71% | -11.01% | 22.45 | 4.24 | 1.25% | -14.07% |
LLY | 301.4B | 28.5B | 4.03% | 16.86% | 48.26 | 10.56 | 0.79% | 11.88% |
MRK | 272.8B | 59.3B | -2.02% | 35.43% | 17.88 | 4.63 | 21.72% | 11.27% |
PFE | 225.5B | 100.3B | -3.66% | -21.92% | 7.19 | 2.25 | 23.43% | 42.74% |
BMY | 144.7B | 46.2B | -3.01% | -5.06% | 22.87 | 3.14 | -0.49% | -9.54% |
MID-CAP | ||||||||
PRGO | 4.6B | 4.5B | -5.71% | -9.25% | -32.73 | 1.03 | 7.56% | -104.06% |
RETA | 3.2B | 2.2M | 98.90% | 143.68% | -10.37 | 1.5K | -80.71% | -4.88% |
SMALL-CAP | ||||||||
SUPN | 1.9B | 667.2M | -4.21% | 13.64% | 31.93 | 2.91 | 15.09% | 13.64% |
TLRY | 1.6B | 602.5M | -7.75% | -62.41% | -2.78 | 2.67 | 18.18% | -18.59% |
CGC | 913.9M | 478.9M | -19.31% | -78.37% | -0.29 | 1.91 | -31.50% | -634.70% |
INVA | 787.4M | 285.2M | -5.32% | -41.91% | 3.57 | 2.76 | -27.21% | -40.28% |
CRON | 745.9M | 114.5M | -6.67% | -53.88% | -4.42 | 6.52 | 27.90% | 57.40% |
ACRS | 542.8M | 29.8M | -32.56% | -54.58% | -6.25 | 18.25 | 340.05% | 4.35% |
OCUL | 396.8M | 51.5M | -13.18% | 0.78% | -5.59 | 7.71 | 18.32% | -984.05% |
ENDP | 94.1M | 2.3B | -43.99% | -88.43% | -0.03 | 0.04 | -22.53% | -376.66% |
Income Statement (Last 12 Months) | ||||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | -29.6% | 2,216,000 | 3,149,000 | 10,000,000 | 11,459,000 | 11,490,000 |
Operating Expenses | 2.6% | 280,250,000 | 273,228,000 | 267,687,000 | 265,291,000 | 256,198,000 |
S&GA Expenses | 1.4% | 109,277,000 | 107,816,000 | 106,282,000 | 103,137,000 | 99,002,000 |
R&D Expenses | 3.4% | 169,843,000 | 164,236,000 | 160,181,000 | 160,916,000 | 155,993,000 |
EBITDA | -2.5% | -310,796,000 | -303,155,000 | -298,089,000 | -290,070,000 | - |
EBITDA Margin | -362.6% | -140 | -30.32 | -26.01 | -25.25 | - |
Earnings Before Taxes | -0.1% | -311,926,000 | -311,535,000 | -304,379,000 | -304,176,000 | -297,836,000 |
EBT Margin | -42.3% | -140 | -98.93 | -30.44 | -26.54 | -25.92 |
Interest Expenses | NaN% | 0.00 | 0.00 | - | - | - |
Net Income | 0.0% | -311,901,000 | -311,784,000 | -304,628,000 | -303,773,000 | -297,386,000 |
Net Income Margin | -42.2% | -140 | -99.01 | -30.46 | -26.51 | -25.88 |
Free Cahsflow | 25.8% | -207,537,000 | -279,869,000 | -275,826,000 | -250,299,000 | -237,030,000 |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | -11.8% | 514 | 584 | 632 | 680 | 735 |
Current Assets | -10.6% | 398 | 445 | 491 | 537 | 596 |
Cash Equivalents | 32.6% | 42.00 | 32.00 | 147 | 532 | 590 |
Net PPE | -0.7% | 11.00 | 11.00 | 11.00 | 11.00 | 12.00 |
Current Liabilities | 16.3% | 59.00 | 51.00 | 46.00 | 44.00 | 54.00 |
Shareholder's Equity | -1554.7% | -65.69 | 5.00 | 69.00 | 128 | 186 |
Retained Earnings | -5.8% | -1,567 | -1,482 | -1,403 | -1,329 | -1,255 |
Additional Paid-In Capital | 1.0% | 1,502 | 1,487 | 1,472 | 1,457 | 1,442 |
Accumulated Depreciation | - | 15.00 | - | - | - | - |
Shares Outstanding | 0.2% | 37.00 | 36.00 | 36.00 | 36.00 | - |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | 26.2% | -204 | -276 | -272 | -248 | -235 |
Share Based Compensation | -0.4% | 59.00 | 59.00 | 58.00 | 58.00 | 57.00 |
Cashflow From Investing | 15.0% | -345 | -405 | -337 | -1.42 | -1.33 |
Cashflow From Financing | 10.7% | 1.00 | 1.00 | 1.00 | 5.00 | 9.00 |
100%
89.6%
80.4%
Y-axis is the maximum loss one would have experienced if Reata Pharmaceuticals was unfortunately bought at previous high price.
34.7%
-16.1%
FIve years rolling returns for Reata Pharmaceuticals.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-23 | MetLife Investment Management, LLC | reduced | -3.98 | 176,946 | 568,748 | -% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | sold off | -100 | -294,000 | - | -% |
2023-03-06 | Rockefeller Capital Management L.P. | added | 17.2 | 107,000 | 245,000 | -% |
2023-03-02 | OLIVER LAGORE VANVALIN INVESTMENT GROUP | new | - | 4,065 | 4,065 | -% |
2023-02-28 | Voya Investment Management LLC | unchanged | - | 250,285 | 739,285 | -% |
2023-02-21 | MACQUARIE GROUP LTD | sold off | -100 | -70,000 | - | -% |
2023-02-16 | HARBOUR INVESTMENTS, INC. | unchanged | - | 342 | 342 | -% |
2023-02-15 | ALLIANCEBERNSTEIN L.P. | added | 224 | 3,428,750 | 4,305,750 | -% |
2023-02-15 | Financial Gravity Asset Management, Inc. | reduced | -24.00 | 15.00 | 19.00 | -% |
2023-02-15 | JANE STREET GROUP, LLC | new | - | 1,961,230 | 1,961,230 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Mar 07, 2023 | perceptive advisors llc | 6.5% | 2,083,799 | SC 13G | |
Feb 14, 2023 | first light asset management, llc | 6.79% | 2,155,552 | SC 13G/A | |
Feb 14, 2023 | point72 asset management, l.p. | 0% | 0 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 8.53% | 2,705,656 | SC 13G/A | |
Feb 03, 2023 | blackrock inc. | 7.9% | 2,501,693 | SC 13G/A | |
Sep 22, 2022 | point72 asset management, l.p. | 5.2% | 1,650,400 | SC 13G | |
Sep 09, 2022 | wellington management group llp | 4.78% | 1,508,638 | SC 13G/A | |
Apr 11, 2022 | ecor1 capital, llc | 6.3% | 1,975,611 | SC 13G | |
Mar 10, 2022 | invesco ltd. | 1.2% | 372,165 | SC 13G/A | |
Feb 10, 2022 | invesco ltd. | 7.2% | 2,280,409 | SC 13G/A |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | - - | - - | - - | - - | - - |
Current Inflation | 0.02 -99.98% | 0.02 -99.98% | 0.03 -99.97% | 0.04 -99.95% | 0.06 -99.93% |
Very High Inflation | - - | - - | - - | - - | - - |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 15, 2023 | 4 | Insider Trading | |
Mar 13, 2023 | 4 | Insider Trading | |
Mar 09, 2023 | 4 | Insider Trading | |
Mar 08, 2023 | 4 | Insider Trading | |
Mar 08, 2023 | 4 | Insider Trading | |
Mar 08, 2023 | 4 | Insider Trading | |
Mar 08, 2023 | 4 | Insider Trading | |
Mar 08, 2023 | 4 | Insider Trading | |
Mar 08, 2023 | 4 | Insider Trading | |
Mar 07, 2023 | 4 | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-03-13 | Bir Dawn Carter | sold | -808,436 | 86.77 | -9,317 | chief commercial officer |
2023-03-10 | Ruff Shamim | sold | -480,610 | 83.73 | -5,740 | - |
2023-03-10 | Ruff Shamim | acquired | 198,042 | 34.5021 | 5,740 | - |
2023-03-07 | WORTLEY MICHAEL D | sold | -34,966 | 84.46 | -414 | chief legal officer |
2023-03-07 | Bir Dawn Carter | acquired | - | - | 41,630 | chief commercial officer |
2023-03-07 | Loewen Andrea | sold | -1,588,140 | 83.4281 | -19,036 | svp, global regulatory affairs |
2023-03-07 | Khan Samina | sold | -330,585 | 83.46 | -3,961 | svp, chief medical officer |
2023-03-07 | Loewen Andrea | acquired | 409,800 | 27.32 | 15,000 | svp, global regulatory affairs |
2023-03-07 | Anand Bhaskar | sold | -13,955 | 84.58 | -165 | svp, chief accounting officer |
2023-03-07 | Soni Manmeet Singh | sold | -52,680 | 84.695 | -622 | coo, cfo and president |
Consolidated Statements of Operations - USD ($) $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Collaboration revenue | |||
Collaboration revenue | $ 2,216 | $ 11,490 | $ 9,019 |
Expenses | |||
Research and development | 169,843 | 155,993 | 159,080 |
General and administrative | 109,277 | 99,002 | 75,128 |
Depreciation | 1,130 | 1,203 | 1,136 |
Total expenses | 280,250 | 256,198 | 235,344 |
Other income (expense), net | (33,892) | (53,128) | (43,914) |
Loss before taxes on income | (311,926) | (297,836) | (270,239) |
Benefit from taxes on income | 25 | 450 | 22,487 |
Net loss | $ (311,901) | $ (297,386) | $ (247,752) |
Net loss per share — basic | $ (8.54) | $ (8.19) | $ (7.35) |
Net loss per share — diluted | $ (8.54) | $ (8.19) | $ (7.35) |
Weighted-average number of common shares used in net loss per share — basic | 36,517,928 | 36,321,351 | 33,709,480 |
Weighted-average number of common shares used in net loss per share — diluted | 36,517,928 | 36,321,351 | 33,709,480 |
License and milestone | |||
Collaboration revenue | |||
Collaboration revenue | $ 1,648 | $ 8,040 | $ 4,701 |
Other revenue | |||
Collaboration revenue | |||
Collaboration revenue | $ 568 | $ 3,450 | $ 4,318 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
---|---|---|
Assets | ||
Cash and cash equivalents | $ 42,312 | $ 590,258 |
Marketable debt securities | 345,202 | 0 |
Prepaid expenses and other current assets | 10,256 | 6,217 |
Total current assets | 397,770 | 596,475 |
Property and equipment, net | 11,179 | 11,604 |
Operating lease right-of-use assets | 105,258 | 126,777 |
Other assets | 284 | 160 |
Total assets | 514,491 | 735,016 |
Liabilities and stockholders’ equity | ||
Accounts payable | 18,706 | 13,505 |
Accrued direct research liabilities | 13,836 | 14,249 |
Other current liabilities | 24,267 | 21,450 |
Operating lease liabilities, current | 2,151 | 3,142 |
Deferred revenue | 0 | 1,648 |
Total current liabilities | 58,960 | 53,994 |
Operating lease liabilities, noncurrent | 117,313 | 132,891 |
Liability related to sale of future royalties, net | 403,913 | 362,142 |
Total noncurrent liabilities | 521,226 | 495,033 |
Commitments and contingencies | ||
Stockholders’ equity: | ||
Additional paid-in capital | 1,501,800 | 1,441,584 |
Accumulated deficit | (1,567,532) | (1,255,631) |
Total stockholders’ equity | (65,695) | 185,989 |
Total liabilities and stockholders’ equity | 514,491 | 735,016 |
Common Stock A | ||
Stockholders’ equity: | ||
Common stock value | 32 | 31 |
Common Stock B | ||
Stockholders’ equity: | ||
Common stock value | $ 5 | $ 5 |